Filter posts

Morning Consult: Medicare’s Flawed Part B Drug Experiment Could Harm Patients

In today’s Morning Consult, the Community Oncology Alliance’s Rose Gerber has an excellent piece detailing …

Will your company be the “Buzz of BIO"?

Anyone who has ever attended the BIO International Convention can attest to the intensity and …

Harvard Analysis of Discriminatory Formulary Design in 2016 Health Plans

BIO supports policy changes that protect patients’ ability to obtain access to the prescription drugs …

The National Kidney Foundation’s KEEP Healthy Screening Emphasizes Early Diagnosis

In the United States, 1 in 9 Americans has kidney disease, and most don’t know …

Star-Telegram: Prescription Drug Price Controls Pose Lethal Problems

In case you missed it, the Fort Worth Star-Telegram ran an op-ed by Thomas P. …

NIH Office of Science Policy Unveils New Resources

The NIH Office of Science Policy (OSP) works on a wide range of issues including …

Judd Gregg: Biodefense Funding Is Crucial to National Security

Writing in the Morning Consult, former Senator Judd Gregg explains critical role of federal programs …

JAMA Study Finds Vast Majority of Requests for Clinical Trial Data Granted

In 2014, BIO members reaffirmed and broadened their commitment to responsibly share data from clinical …

ICYMI: John Lechleiter: An Empty Obama-Clinton-Sanders Plan on Drug Costs

Writing in the Wall Street Journal today, Eli Lilly and Company Chairman, President and CEO …

March is National Colon Cancer Awareness Month

In 2000, President Clinton officially dedicated March as National Colon Cancer Awareness Month. Since then, …